PPAR-γ regulates pharmacological but not physiological or pathological osteoclast formation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

23 citing papers in PubMed.

1. The role of bone in whole-body energy metabolism.Nature reviews. Endocrinology · 2025
   Review
2. Exogenous activation of the adhesion GPCR ADGRD1/GPR133 protects against bone loss by negatively regulating osteoclastogenesis.Science advances · 2025
   Article
3. Neoandrographolide inhibits mature osteoclast differentiation to alleviate bone loss and treat osteoporosis.Frontiers in pharmacology · 2025
   Article
4. Effects of Systemic Peroxisome Proliferator-Activated Receptor Gamma Inhibition on Bone and Immune Cells in Aged Female Mice.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024
   Article
5. Sexual dimorphism of osteoclast reliance on mitochondrial oxidation of energy substrates in the mouse.JCI insight · 2023
   Article
6. A Zeb1/MtCK1 metabolic axis controls osteoclast activation and skeletal remodeling.The EMBO journal · 2023
   Article
7. The Potential Therapeutic Role of Metformin in Diabetic and Non-Diabetic Bone Impairment.Pharmaceuticals (Basel, Switzerland) · 2022
   Review
8. Senescent preosteoclast secretome promotes metabolic syndrome associated osteoarthritis through cyclooxygenase 2.eLife · 2022
   Article
9. The Dibenzyl Isoquinoline Alkaloid Berbamine Ameliorates Osteoporosis by Inhibiting Bone Resorption.Frontiers in endocrinology · 2022
   Article
10. RANKL from bone marrow adipose lineage cells promotes osteoclast formation and bone loss.EMBO reports · 2021
    Article
11. PPARG in osteocytes controls sclerostin expression, bone mass, marrow adiposity and mediates TZD-induced bone loss.Bone · 2021
    Article
12. Glucose Metabolism in Osteoblasts in Healthy and Pathophysiological Conditions.International journal of molecular sciences · 2021
    Review
13. Lack of Adiponectin Drives Hyperosteoclastogenesis in Lipoatrophic Mice.Frontiers in cell and developmental biology · 2021
    Article
14. Increased marrow adipogenesis does not contribute to age-dependent appendicular bone loss in female mice.Aging cell · 2020
    Article
15. Cytisine attenuates bone loss of ovariectomy mouse by preventing RANKL-induced osteoclastogenesis.Journal of cellular and molecular medicine · 2020
    Article
16. Nuclear receptors in osteoclasts.Current opinion in pharmacology · 2020
    Review
17. Osteoclast-mediated bone resorption is controlled by a compensatory network of secreted and membrane-tethered metalloproteinases.Science translational medicine · 2020
    Article
18. Characterizing how probioticBone reports · 2019
    Article
19. Activation of PPARs Modulates Signalling Pathways and Expression of Regulatory Genes in Osteoclasts Derived from Human CD14+ Monocytes.International journal of molecular sciences · 2019
    Article
20. ASXL1 impairs osteoclast formation by epigenetic regulation of NFATc1.Blood advances · 2018
    Article

Corrections and comments

• Commented on by
  Reply to "PPAR-γ regulates pharmacological but not physiological or pathological osteoclast formation".2016

Authors and funding

6 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as